Maspin-based peptides and methods of use thereof
The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.
1. A composition comprising an isolated peptide or polypeptide that comprises a portion with at least 90% sequence identity with the entire length of one or more of SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7.
2. The composition of claim 1 , wherein said peptide or polypeptide comprises a portion with 100% sequence identity with the entire length of one of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.
3. The composition of claim 2 , wherein said peptide or polypeptide comprises 100% sequence identity with SEQ ID NO:5.
4. The composition of claim 2 , wherein said peptide or polypeptide comprises 100% sequence identity with SEQ ID NO:6.
5. The composition of claim 2 , wherein said peptide or polypeptide comprises 100% sequence identity with SEQ ID NO:7.
6. A pharmaceutical composition comprising: (a) one or more of: (i) a peptide or polypeptide with at least 90% sequence identity with the entire length of SEQ ID NO:5, (ii) a peptide or polypeptide with at least 90% sequence identity with the entire length of SEQ ID NO:6; and a peptide or polypeptide with at least 90% sequence identity with the entire length of SEQ ID NO:7; and (b) a physiologically suitable buffer.
7. A pharmaceutical composition comprising: (a) one or more of compositions of claim 1 ; and (b) a physiologically suitable buffer.
8. A method of enhancing cell adhesion comprising administering an effective amount of a composition of claim 1 to a cell, tissue, or subject.
9. The method of claim 8 , wherein enhancing cell adhesion results in reduced cell motility.
10. The method of claim 8 , wherein said cell, tissue, or subject comprises cancer cells, or cells at risk of metastasis.
11. The method of claim 8 , wherein said peptide or polypeptide physically associates with uPAR, β1 integrin, or both upon administering to said cell, tissue, or subject.
12. The method of claim 8 , wherein said peptide or polypeptide localizes at the cell surface upon administration to said cells, tissue, or a subject.
13. The method of claim 8 , wherein said peptide or polypeptide co-localizes with the uPA/uPAR complex.
14. A method of treating cancer or metastasis comprising administering to a cell, tissue, or subject an effective amount of a composition of claim 1 , wherein said administering said peptide or polypeptide enhances cell adhesion and/or inhibits cell motility.
15. A method of treating a bone formation disorder comprising administering to a cell, tissue, or subject an effective amount of a composition of claim 1 .